Pregabalin - Pfizer

Drug Profile

Pregabalin - Pfizer

Alternative Names: CI 1008; Isobutylgaba; Lyrica; PD 144723; Pregabalin oral solution

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwestern University
  • Developer Eisai Co Ltd; Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
  • Phase III Tonic-clonic epilepsy
  • Discontinued Pain; Postoperative pain; Restless legs syndrome

Most Recent Events

  • 13 Mar 2018 Pfizer completes a phase III trial in Partial epilepsies (Adjunctive treatment, In infants, In children) in USA, Belgium, Argentina, Germany, Hungary, Spain, Belarus, Bulgaria, China, France, Greece, Israel, South Korea, Malaysia, the Netherlands, Philippines, Romania, Russia, Serbia, Singapore, Slovakia, Taiwan, Thailand, Turkey, Poland, Portugal, Bosnia and Herzegovina, Lebanon and Ukraine (NCT02072824)
  • 03 Nov 2017 Efficacy and adverse events data from a phase III trial in Fibromyalgia presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 08 Jun 2017 Pregabalin launched for Fibromyalgia and Neuropathic pain (PO, orally disintegrating) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top